难治性/复发性弥漫大B细胞淋巴瘤的生物治疗被引量：1

Biotherapy of relapsed/refractory diffuse large B-cell lymphoma

下载PDF

导出

摘要尽管弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者的总体预后有所改善,但仍有大约三分之一患者属于难治性/复发性DLBCL,这是导致其发病率和病死率增加的主要原因。临床上治疗难治性/复发性DLBCL的方法仍以大剂量化疗以及对无并发症的患者进行大剂量化疗-自体干细胞移植(high-dose chemotherapy-autologous stem cell trans-plant,HD-ASCT)为主。但对于给予利妥昔单抗联合CHOP化疗(rituximab-CHOP,R-CHOP)治疗后无反应的难治性DLBCL患者进行HD-ASCT,预后极差。因此,如何提高难治性/复发性DLBCL患者总生存期成了新的研究热点。本文主要从治疗方面对难治性/复发性DLBCL进行综述。

作者史丽君陈林

机构地区重庆医科大学附属第二医院血液科

出处《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2013年第1期115-119,共5页 Chinese Journal of Cancer Biotherapy

基金重庆市卫生局科研项目(No.2009-2-21)~~

关键词弥漫大B细胞淋巴瘤难治性复发性大剂量化疗-自体干细胞移植

分类号 R733.4 [医药卫生—肿瘤] R730.54 [医药卫生—肿瘤]

引文网络
相关文献

参考文献40

1Friedberg JW. The American society of hematology education program book[M].California,American Society of Hematology,2011.498-505.
2Johnston PB,Wiseman GA,Micallef INM. Positron emission tomography using F-18 fluorodeoxyglucose pre-and post-autologous stem cell transplant in non-Hodgkin's lymphoma[J].Bone Marrow Transplantation,2008,(11):919-925.doi:10.1038/bmt.2008.82.
3Martín A,Conde E,Arnan M. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma:The influence of prior exposure to rituximab on outcome.A GEL/TAMO study[J].Haematologica,2008,(12):1829-1836.
4Cciffier B,Thieblemont C,van den Neste E. Long-term outcome of patients in the LNH-98.5 trial,the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:A study by the Grouped' Etudes des Lymphomes de l" Adulte[J].Blood,2010,(12):2040-2045.
5田昱平,姚亚洲,彭飞.利妥昔单抗联合常规化疗治疗B细胞淋巴瘤随机对照试验的Meta分析[J].中国肿瘤生物治疗杂志,2011,18(1):63-69. 被引量：9
6Gisselbrecht C,Glass B,Mounier N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era[J].Journal of Clinical Oncology,2010,(27):4184-4190.
7Chen YB,Hochberg EP,Feng Y. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab,cyclophosphamide,adriamycin,vincristine,and prednisone therapy compared to patients who failed cyclophosphamide,adriamycin,vincristine,and prednisone[J].Leukemia and Lymphoma,2010,(05):789-796.
8Elstrom RL,Martin P,Ostrow K. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma:Implications for the development of novel therapeutic strategies[J].Clin Lymphoma Myeloma Leuk,2010,(03):192-196.
9Friedberg JW. The American Society of Hematology education program book[M].California,American Society of Hematology,2005.329-334.
10Armitage JO,Carbone PP,Connors JM. Treatment-related myelodysplasia and acute leukemiain non-Hodgkin's lymphoma patients[J].Journal of Clinical Oncology,2003,(05):897-906.

二级参考文献20

1林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量：49
2Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 [ J]. Blood, 2006, 107( 1 ) : 265-276.
3Morton LM, Wang SS, Cozen W, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes [ J]. Blood, 2008, 112 (13) : 5150-5160.
4Capietto AH, Keirallah S, Gross E, et al. Emerging concepts for the treatment of hematological malignancies with therapeutic mono- clonal antibodies [J]. Curr Drug Targets, 2010, 11 (7) : 790- 800.
5Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform Meta-analysis of the published literature for survival end- points [J]. Stat Mcd, 1998, 17(24): 2815-2834.
6Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximah compared with CHOP alone in elderly patients with dif- fuse large-B-cell lymphoma [J]. N Engl J Med, 2002, 346(4) : 235 -242.
7Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of re- sponse duration after salvage therapy with a combination of ritux- imab, fludarabine, cyclophosphamide, and mitoxantrone (R- FCM) in patients with recurring and refractory follicular and man- tle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) [ J]. Blood, 2006, 108 ( 13 ) : 4003-4008.
8Herold M, Pasold R, Sroek S. Results of a prospective randomised open label phase Ⅲ study comparing rituximab plus mitoxantrone, eblorambueile, prednisolone chemotberapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin' s lymphoma (NHL) and mantle-cell-lyrnphoma (MCL) [J]. ASH Annual Meeting Abstracts. 2004. 104( 11 ) : 584.
9Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOF) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [ J ]. Blood, 2005, 106 ( 12 ) : 3725-3732.
10Lenz G, Dreyling M, Hoster E, et ah Immanochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously un- treated mantle ceil lymphoma: Results of a prospective randonaized trial of the German Low Grade Lymphoma Study Group (GLSG) [J]. JClin Oncol, 2005, 23(9): 1984-1992.